72 Pinchas Rosen Street Tel Aviv 69512 Israel
Phone: 972-3-765-8585 www.compugen.co.il



Compugen combines the fields of advanced mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics. The company’s principal technologies include Gencarta, LEADS, DNA Chip design, Z3 (a high-throughput 2-D gel electrophoresis analysis system) and LabOnWeb.com.

LEADS allows thorough mining of expressed sequence tag databases, combined analysis of EST and genomic data and polymorphism detection and qualification. Gencarta is an annotated genome, transcriptome and proteome database and query tool based on the LEADS algorithm-driven platform. LabOnWeb.com was launched in December 1999 and provides a web portal to some of Compugen’s products.

Founded in 1993, Compugen went public in August 2000, raising $50 million.


The company has collaborations with Avalon Pharmaceuticals, Wyeth-Ayerst, Serono and Millennium Pharmaceuticals Inc., among others. Compugen and Gene Logic Inc., of Gaithersburg, Md., announced a collaboration involving their databases in January 2002. The companies said they will integrate Compugen's human Gencarta annotated genomic and proteomic database with the gene expression information in Gene Logic's GeneExpress Suite. Financial terms of the collaboration were not disclosed.